UBE2T and gastric cancer: M435-1279, a novel UBE2T inhibitor that inhibits the over-excitation of the Wnt/β-catenin signaling pathway by blocking the UBE2T-mediated degradation of RACK1, has been shown to play a role in gastric cancer and provides insights for the treatment of CC (Anastas and Moon 2013).